Evidence map›Paper›PMID 34256065›Full record

ArticleJournal of hepatology2021

Systemic treatment of hepatocellular carcinoma: An EASL position paper.

Jordi Bruix, Stephen L Chan, Peter R Galle, Lorenza Rimassa, Bruno Sangro

Registry-linked trialAbstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05543304 (Predicting Response to Systemic Therapies for Hepatocellular Carcinoma), which is not on this map. Cited by 221 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
221citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05543304 unknown statusnot on this map

Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) Based on Clinical Variables and Radiomics Data With Machine Learning Methods

TypeobservationalSponsorFirst Affiliated Hospital of Wenzhou Medical UniversityRan2018 to 2024Enrolled200ConditionsHepatocellular Carcinoma Non-resectable, Effect of DrugArmsradiological evaluation
3 · Its place in the literature

Who cites it

221 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024
    Guideline
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. AI-assisted ascites volumetry for prognostic stratification in HCC treated with Atezolizumab/Bevacizumab.Cancer imaging : the official publication of the International Cancer Imaging Society · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

161 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jordi BruixBCLC Group, Liver Unit, Hospital Clínic, University of Barcelona, IDIBAPS, CIBEREHD, Barcelona, Spain.
Stephen L ChanDepartment of Clinical Oncology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, China.
Peter R GalleUniversity Medical Center Mainz, Mainz, Germany.
Lorenza RimassaDepartment of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Bruno SangroLiver Unit and HPB Oncology Area, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain. Electronic address: bsangro@unav.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The last 5 years have witnessed relevant advances in the systemic treatment of hepatocellular carcinoma. New data have emerged since the development of the EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma in 2018. Drugs licensed in some countries now include 4 oral multi-tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib and cabozantinib), 1 anti-angiogenic antibody (ramucirumab) and 4 immune checkpoint inhibitors, alone or in combination (atezolizumab in combination with bevacizumab, ipilimumab in combination with nivolumab, nivolumab and pembrolizumab in monotherapy). Prolonged survival in excess of 2 years can be expected in most patients with sensitive tumours and well-preserved liver function that renders them fit for sequential therapies. With different choices available in any given setting, the robustness of the evidence of efficacy and a correct matching of the safety profile of a given agent with patient characteristics and preferences are key in making sound therapeutic decisions. The recommendations in this document amend the previous EASL Clinical Practice Guidelines and aim to help clinicians provide the best possible care for patients today. In view of several ongoing and promising trials, further advances in systemic therapy of hepatocellular carcinoma are foreseen in the near future and these recommendations will have to be updated regularly.

Indexed as

Carcinoma, HepatocellularHumansInternal MedicineLiver Neoplasmshepatomaimmune-checkpoint inhibitorsimmunotherapyliver cancerliver toxicitytyrosine kinase inhibitors

Identifiers

PMID34256065

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.